New product: Orfadin (nitisinone) 4mg/ml Oral Suspension -

New product: Orfadin (nitisinone) 4mg/ml Oral Suspension
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Nutritional and metabolic disorders | Paediatric and neonatal medicine
Summary
This product is licensed for the treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
UKMi comment
This new paediatric oral suspension formulation of nitisinone (which was previously only available as capsules) will help facilitate accurate dosing for infants and small children.
Related links: